medigraphic.com

2021, Number 3

<< Back Next >>

Folia 2021; 15 (3)

Steven Johnson syndrome

Daza VJT, Gutiérrez AEY, O´Farril HV

Language: Spanish
References: 32
Page: 1-14
PDF size: 503.72 Kb.


ABSTRACT

Introduction: Stevens Johnson syndrome is a severe acute dermatosis, often fatal. It is characterized by general malaise, stomatitis, purulent conjunctivitis and vesiculobullous lesions disseminated over the entire body surface. It is triggered by viral or bacterial infections, and mainly by medications.
Objective: To keep informed etiology, clinical manifestations and treatment of Stevens Johnson syndrome.
Methods: A review was carried out of the literature available in SciELO, bvscuba, PubMed Central, Medline, and Clinicalkey databases, in English and Spanish. The descriptors used were Stevens Johnson syndrome and drugs. During the review process, 32 articles were cited, including 6 books and 26 journals, 50% updated in the last 5 years. Basic concepts related to this syndrome and the clinical manifestations, etiopathogenesis, positive diagnosis, differentials and finally the treatment were reviewed.
Conclusions: Stevens Johnson syndrome is a rare, serious bullous mucocutaneous disease that can lead to death in the patient.


REFERENCES

  1. L, Katz S, Gilchrest B, Paller A, Leffell D, Wolff K. Fitzpatrick Dermatología enMedicina General. Tomo II. 8 ed. Buenos Aires: Editorial Panamericana; 2016. p. 963.

  2. Bolognia JL, Schaffer JV, Cerroni L. Dermatología. 4 ed. USA: Elsevier; 2018.

  3. Arenas R. Dermatología Atlas, diagnóstico y tratamiento. 7 ed. México: McGRAWHILLINTERAMERICANA; 2019.

  4. Falabella R, Victoria Chaparro J, Barona Cabal MI. Fundamentos de MedicinaDermatología. 8 ed. Medellín, Colombia: CIB fondo editorial; 2017.

  5. James W, Berger T, Dirk E. Andrews' Diseases of the Skin. 13th ed. New York:Elsevier; 2019.

  6. Halevy S, Ghislain PD, Mockenhaupt M. Allopurinol is the most common cause ofStevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J AmAcad Dermatol. 2008;58(1):25-32.

  7. Lin YF, Yang CH, Sindy H. Severe cutaneous adverse reactions related to systemicantibiotics. ClinI Infect Dis. 2014;58(10):1377-85.

  8. Fernandez FA, Pintor E, Quesada R, Garces FJ. Toxic epidermal necrolysis inducedby phenytoin and whole brain radiotherapy. Actas Dermosifiliogr. 2007;98(7):483-5.

  9. Sanz-Muñoz C, Martinez-Moran C, Torrero-Anton MV, Miranda-Romero A.Indapamide-associated Stevens-Johnson syndrome. Actas Dermosifiliogr.2008;99(4):321-2.

  10. Khafaga YM, Jamshed A, Allam AA. Stevens-Johnson syndrome in patients onphenytoin and cranial radiotherapy. Acta Oncol. 1999;38(1):111-6.

  11. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of thelymphocyte transformation test in the diagnosis of drug sensitivity: dependence on itstiming and the type of drug eruption. Allergy. 2007;62(12):1439-44.

  12. Choi HJ, Ku JK, Kim MY. Possible role of Fas/Fas ligand-mediated apoptosis in thepathogenesis of fixed drug eruption. Br J Dermatol. 2006;154(3):419-25.

  13. Viard-Leveugle I, Gaide O, Jankovic D. TNF-alpha and IFN-gamma are potentialinducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitricoxide synthase in toxic epidermal necrolysis. J Invest Dermatol. 2018;133(2):489-98.

  14. Kumar V, Abbas KA, Fausto N, Aster JC. Robbins y Cotran. Patología estructural yfuncional. 8 ed. España: Elsevier; 2010.

  15. Goldsmith 15. Sassolas B, Haddad C, Mockenhaupt M. ALDEN, an algorithm forassessment of drug causality in Stevens-Johnson Syndrome and toxic epidermalnecrolysis: comparison with case control analysis. Clin Pharmacol Ther. 2010;88(1):60-8.

  16. Barbaud A, Collet E, Milpied B. A multicentre study to determine the value and safetyof drug patch tests for the three main classes of severe cutaneous adverse drug reactions.Br J Dermatol. 2013;168(3):555-62.

  17. Harr T, French LE. Severe cutaneous adverse reactions: acute generalizedexanthematouspustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.Med Clin North Am. 2018;94(4):727-42.

  18. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnsonsyndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J.2002;8(1):5.

  19. Araki Y, Sotozono C, Inatomi T. Successful treatment of Stevens-Johnson syndromewith steroid pulse therapy at disease onset. Am J Ophthalmol. 2019;147(6):1004-11.

  20. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnsonsyndrome/toxic epidermal necrolysis. Acta DermVenereol. 2007;87(2):144-8.

  21. Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnsonsyndrome andtoxic epidermal necrolysis and retrospective comparison with systemic corticosteroid.Indian J DermatolVenereolLeprol. 2013;79(5):686-92.

  22. Valeyrie-Allanore L, Wolkenstein P, Brochard L. Open trial of ciclosporin treatmentfor Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol.2010;163(4):847-53.

  23. Viard I, Wehrli P, Bullani R. Inhibition of toxic epidermal necrolysis by blockade ofCD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490-3.

  24. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatorydiseases. N Engl J Med. 2012;367(21):2015-25.

  25. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode ofaction and practical use in dermatology. Acta Derm Venereol. 2018;87(3):206-18.

  26. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative studyshowing no benefit on mortality or progression. Arch Dermatol. 2003;139(1):33-6.

  27. Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in thetreatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinesepatients: a retrospective study of 82 cases. Eur J Dermatol. 2010;20(6):743-7.

  28. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects oftreatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis:A retrospective study on patients including the prospective EuroSCAR Study. J Am AcadDermatol. 2008;58(1):33-40.

  29. Lee HY, Lim YL, Thirumoorthy T, Pang SM. The role of intravenousimmunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patientsmanaged in a specialized centre. Br J Dermatol. 2013;169(6):1304-9.

  30. Yang Y, Xu J, Li F, Zhu X. Combination therapy of intravenous immunoglobulin andcorticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnsonsyndrome: a retrospective comparative study in China. Int J Dermatol. 2009;48(10):1122-8.

  31. Redondo P, de Felipe I, de la Pena A, Aramendia JM, Vanaclocha V. Drug-inducedhypersensitivity syndrome and toxic epidermal necrolysis. Treatment with Nacetylcysteine.Br J Dermatol. 1997;136(4):645-6.

  32. Paquet P, Jennes S, Rousseau AF, Libon F, Delvenne P, Pierard GE. Effect of Nacetylcysteinecombined with infliximab on toxic epidermal necrolysis. A proof-ofconceptstudy. Burns. 2019;40(8):1707-12.




2020     |     www.medigraphic.com